Skip to main navigation

Investors
News Releases
Events & Presentations
Stock Information
Corporate Governance
SEC Filings
IR Resources

News Releases

News Releases

Year

April 27, 2020

Harpoon Therapeutics Doses First Patient with HPN217, a BCMA Targeting TriTAC, for Multiple Myeloma

April 1, 2020

Harpoon Therapeutics Appoints Two New Members to Its Board of Directors

March 12, 2020

Harpoon Therapeutics Reports Fourth Quarter 2019 Financial Results and Provides Corporate Update

March 5, 2020

Harpoon Therapeutics to Report Fourth Quarter 2019 Financial Results and Provide Corporate Update

February 20, 2020

Harpoon Therapeutics to Participate in Two Upcoming Investor Conferences

November 26, 2019

Harpoon Therapeutics to Participate in the Piper Jaffray Healthcare Conference

November 21, 2019

Harpoon Therapeutics and AbbVie Announce Licensing and Option Collaboration to Advance HPN217, Harpoon’s BCMA-Targeting TriTAC®, and Expand Existing Discovery Collaboration

November 12, 2019

Harpoon Therapeutics to Participate in Two Upcoming Investor Conferences

November 6, 2019

Harpoon Therapeutics Reports Third Quarter 2019 Financial Results and Provides Corporate Update

October 29, 2019

Harpoon Therapeutics Presents Preclinical Data for HPN328, a DLL3-targeting T Cell Engager, at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Pagination

First page
Previous page
Page 1
Page 2
Page 3
Page 4
Current page 5
Page 6
Page 7
Page 8
Next page
Last page

Email Alerts

RSS Feeds

Contact IR

Search

© 2021. Harpoon Therapeutics, Inc. All rights reserved.

Search Investor Relations